U.S. Private Equity Firm Set To Win Sanofi's Consumer Health Division

A proposed offer from Clayton, Dubilier & Rice (CD&R) would result in the sale of Sanofi’s 50% stake in Opella, which makes over-the-counter medicine such as Doliprane and Allegra, Indrabati Lahiri reported for Euronews.

Sanofi has been trying to divest this unit for about a year in an attempt to focus more on its core products. I Photo: Sanofi

The deal for the pharmaceutical giant is one of the biggest of its kind. It is likely to give CD&R a controlling stake in the division and is estimated to be worth about €15 billion.

Sanofi has been trying to divest this unit for about a year in an attempt to focus more on its core products, which include treatments for rare diseases, cancer, and other health issues.

Currently, Opella is headquartered in France, and besides Doliprane and Allegra, it also includes products like Novanight, Dulcolax, and Icy Hot.

It produces a wide range of supplements, vitamins, and minerals, serving more than half a billion global customers. Opella operates in 100 countries with over 11,000 employees and has four innovation and research centers as well as 13 manufacturing sites.